FILING ANALYSIS · MONDAY, NOVEMBER 16

Prelude Therapeutics Inc PRLD — 8-K: Results of Operations and Financial Condition

neutral

Prelude Therapeutics reported its Q3 2026 financial results and provided a corporate update, including the enrollment of a Phase 1 study for PRT13722 and a clinical trial collaboration with Lilly, with initial proof of concept data anticipated in the 2nd half of 2027. The company has a cash runway expected into the second quarter of 2028 with $142.7 million in cash and cash equivalents as of Septe

The filing

8-K - Prelude Therapeutics Inc (0001678660) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+